You are here

  • Home
  • Archive
  • Volume 20, Issue 5
  • Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer

Article metrics

Article menu
Download PDFPDF
Ovarian Cancer
Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer

 

Online download statistics by month:

Online download statistics by month: March 2019 to September 2024

AbstractFullPdf
Mar 20191801
Apr 20192200
May 20193101
Jun 20191800
Jul 20192202
Aug 20191000
Sep 20191000
Oct 2019800
Nov 20191300
Dec 20191200
Jan 20204602
Feb 20201100
Mar 20201700
Apr 20201401
May 20202500
Jun 20202200
Jul 20205200
Aug 20201400
Sep 20202001
Oct 20202001
Nov 20202000
Dec 20201200
Jan 20212601
Feb 20211100
Mar 20211300
Apr 20211500
May 20211200
Jul 2021100
Aug 2021100
Sep 2021200
Oct 20212200
Nov 20211900
Dec 20213500
Jan 20224702
Feb 20223200
Mar 20226901
Apr 202213401
May 20224001
Jun 20225001
Jul 20223404
Aug 20225901
Sep 202210300
Oct 20225300
Nov 20227801
Dec 20224203
Jan 20232600
Feb 202311302
Mar 20235300
Apr 20235701
May 20232901
Jun 2023900
Jul 20232801
Aug 20233100
Sep 20232900
Oct 20238002
Nov 20233502
Dec 20234200
Jan 20243600
Feb 20243601
Mar 20247200
Apr 20244700
May 20243500
Jun 20243601
Jul 20246300
Aug 20242700
Sep 2024600
Total2225036